DLDennis Lawin

Dennis Lawin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dennis Lawin has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiac Biomarkers to Refine Pretest Probability for Coronary Obstruction and Predict Survival After Revascularization in Chronic Coronary Syndrome

    by Andrej Teren, Jeffrey Netto, Joachim Thiery, Holger Thiele, Christoph Stellbrink, Dennis Lawin, Thorsten Lawrenz, Anselm Artur Derda, Sylvia Henger, Holger Kirsten, et al.

    Background: The diagnostic and prognostic roles of cardiovascular biomarkers in chronic coronary syndrome remain unclear. Methods: Patients undergoing coronary angiography for suspected chronic coronary syndrome were prospectively enrolled (n=2251; median follow‐up 12.6 years). Obstructive coronary artery disease was defined as ≥50% stenosis in ≥1 major epicardial vessel. HsTnT (high‐sensitivity cardiac troponin T), NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity C‐reactive protein, interleukin‐6, and copeptin were measured. Receiver operating characteristic analysis and Cox regression with biomarker × treatment interaction testing were performed. Results: Overall, 888 patients (39.4%) had obstructive coronary artery disease. Only hsTnT showed meaningful diagnostic capacity (area under the curve 0.669; risk factor‐weighted clinical likelihood area under the curve 0.663), with incremental benefit inversely proportional to risk factor‐weighted clinical likelihood category (Δ area under the curve: very low 10.4%, low 8.0%, intermediate/high 5.0%). NT‐proBNP was the strongest mortality predictor across optimal medical therapy (hazard ratio [HR], 1.488 [95% CI, 1.288–1.720], P P =0.029), and coronary artery bypass grafting (HR, 1.220 [95% CI, 1.049–1.420], P =0.010). Interaction analysis validated a data‐derived 150 pg/mL threshold ( P =0.032): below it, mortality was comparably low regardless of revascularization (HR, 0.98 [95% CI, 0.67–1.43], P =0.910); above it, baseline risk was markedly elevated (HR, 5.75 [95% CI, 4.10–8.00], P P <0.001). Conclusions: HsTnT provides risk factor‐weighted clinical likelihood category‐specific incremental diagnostic value. NT‐proBNP is a universal prognostic marker identifying patients with distinct revascularization‐associated mortality reduction driven by differential baseline risk. Registration: URL: https://clinicaltrials.gov/study/NCT00497887 ; Unique Identifier: NCT00497887.

  • Open Access

    Prolonged Smartphone-Based Photoplethysmography for Heart Rhythm Monitoring After Repeat Ablation of Atrial Fibrillation — A 6-Month Prospective Study on mHealth Compliance, Motivation and Arrhythmia Recurrence

    by Dennis Lawin, Alina Hoffmann, Thorsten Lawrenz, Sophia Schulze Lammers, Sebastian Kuhn, Stijn Evens, Thomas De Cooman, Christoph Stellbrink


  • Prospective evaluation of low voltage-guided repeat ablation of atrial fibrillation

    by Dennis Lawin, Christoph Stellbrink, Sophia Schulze Lammers, Alina Hoffmann, Andrej Teren, Thorsten Lawrenz

    Background Atrial fibrillation (AF) recurrences following pulmonary vein isolation (PVI) remain a substantial challenge. Aims To evaluate repeat ablation of AF combining PVI with substrate-based left atrial ablation targeting low voltage areas (LVA). Methods Patients with recurrent AF after prior solely PVI were enrolled. Voltage map was conducted during sinus rhythm. Repeat PVI was performed in case of PV-reconnection. Only if LVA (defined as electrogram amplitudes < 0.5 mV) were present, substrate modification was conducted by creating linear or box lesions. Arrhythmia monitoring was performed for 6 months using a photoplethysmography-based smartphone application. Results 58 patients were analysed (37.9% female, median age 66.0 years [IQR 59.8–72.3]). Reconnection of at least 1 PV was found in 49 patients (84.5%). LVA were found in 31 patients (53.4%). An anterior box lesion was created in 39.7%, anterior linear lesion in 8.6%, posterior box lesion in 17.2%, roof line in 34.5%, and posterior mitral isthmus line in 5.2% of the patients. Patients with LVA were more often female (54.8% vs. 18.5% without LVA; p = 0.0045), were at higher age (71.0 years [IQR 66.0–78.0] vs. 62.0 years [IQR 55.0–66.0] without LVA; p < 0.0001), and had higher left atrial volume indexes (50.0ml/m2 [IQR 40.0–61.0] vs. 34.0ml/m2 [IQR 28.0–48.0] without LVA; p = 0.0014). Arrhythmia-free survival was 66.7% in patients without LVA and 48.4% in patients with LVA (HR 0.6063; 95% CI:0.2767–1.329; p = 0.2206). Conclusion PV reconnection and the presence of LVA constitute the main findings of repeat ablations of AF. Repeat PVI combined with a tailored ablation approach individually targeting LVA was effective and safe. Graphical Abstract


  • Open Access

    Digitale Kardiologie in Studium und Weiterbildung

    by Dennis Lawin, Dominik Hubricht, Ilja Bergt, Hannah Billig

    Zusammenfassung: Die Digitalisierung eröffnet Chancen, medizinisches Wissen jederzeit zugänglich zu machen. Aktuell werden digitale Tools wie Clinical Decision Support-Systeme, Leitlinien, Score-Kalkulatoren sowie spezialisierte Apps in der ärztlichen Weiterbildung und im klinischen Alltag genutzt. Auch eLearning-Plattformen, virtuelle Fallstudien und Simulationen unterstützen Medizinstudierende und Ärzt*innen in ihrer Qualifizierung. Digitale Tools spielen zudem eine wichtige Rolle in der Kommunikation unter Ärzt*innen und mit der Öffentlichkeit via Social Media. Allerdings fehlt es an standardisierten Qualitätskriterien für diese Inhalte, was eine kritische Prüfung der Vertrauenswürdigkeit erfordert. Trotz des Potenzials sind digitale Lehrinhalte noch unzureichend im Studium verankert. Eine stärkere Integration könnte das Lernen zukunftsorientiert weiterentwickeln und die Ausbildungsqualität verbessern.

  • Open Access

    Echocardiography Correlation with Seismocardiography—Systematic Review

    by Dennis Lawin, Ulf Kulau, Urs-Vito Albrecht

    A methodological systematic review included literature retrieved from Scopus, PubMed, and IEEE-Explore. 61 studies on seismocardiography (SCG) and echocardiography (ECHO) were found. After screening for aortic and mitral valve timing events, 12 studies were selected. These studies focused on correlating SCG signals with ECHO using M-mode, PW-Doppler, CW-Doppler, and TDI. Variations in sensor placement and subject positioning highlighted the need for standardization. Our review stresses the importance of clear objectives, standardized protocols, and recording disease-specific impacts on heart mechanics for future research.

  • Open Access

    Developing a Protocol for Aligning and Correlating Seismocardiography with Echocardiography

    by Dennis Lawin, Ulf Kulau, Urs-Vito Albrecht

    Seismocardiography (SCG) monitors health metrics through body surface vibrations from heart activity. The BEAT experiment required echocardiography (ECHO) to correlate SCG signals with cardiac events. Since no standardized ECHO protocol existed, the authors developed one. The protocol focused on recording mitral and aortic valve openings and closings using multiple ECHO modalities for accuracy, ensuring usability, comfort, and efficient data collection. It was tested on healthy subjects and allowed post-hoc analysis of cardiac function. This standardized protocol aims to enhance comparability across SCG studies and offers a reliable method for correlating SCG signals with cardiac events.

  • Open Access

    Impact of atrial fibrillation diagnosis-to-ablation time on 24-month efficacy and safety outcomes in the Cryo Global Registry

    by Dennis Lawin, Christoph Stellbrink, Kyoung-Ryul Julian Chun, Cheng-Hung Li, Kelly A van Bragt, Fred Kueffer, Jada M Selma, Il-Young Oh, Jean Manuel Herzet, Junichi Nitta, et al.

    Aims: Early rhythm control therapy in atrial fibrillation (AF) results in higher freedom from atrial arrhythmia (AA) recurrence and improved cardiovascular outcomes. The optimal timing of cryoballoon ablation (CBA) is unknown. Methods and results: We evaluated AA recurrence and procedure-related complications of early vs. late CBA (≤12 vs. >12 months from diagnosis) in patients enrolled in the prospective Cryo Global Registry (121 centres in 37 countries, NCT02752737). A total of 3447 subjects were followed through 12 months and 1220 through 24 months. In summary, 1573 patients (46%) had early ablation at a median (IQR) of 0.3 (0.1–0.6) years from AF diagnosis (age 62 ± 12 years., 35.8% female, 71.4% paroxysmal), and 1874 (54%) had late ablation at a median of 3.4 (1.9–6.7) years after diagnosis (age 61 ± 11 years, 36.2% female, 75.0% paroxysmal). Early ablation patients were less hypertensive (53.5% vs. 57.9%, P = 0.01) and less symptomatic (1.5 ± 1.1 vs. 1.8 ± 1.1 symptoms/patient, P < 0.01) and had smaller left atrial diameters (41 ± 7 mm vs. 42 ± 7 mm, P < 0.01). Freedom from AA recurrence was 81.5% (95% CI: 78.7–83.9%) in the early vs. 71.7% (95% CI: 68.9–74.3%) in the late ablation group at 24 months (P < 0.01). The risk of cardioversion was 41% lower in the early ablation group [HRAdj: 0.59 (0.42–0.83), P < 0.01]. Serious procedure-related adverse events occurred in 2.4 and 3.5% of patients in the early and late ablation groups (P = 0.045), respectively. Conclusion: CBA within 12 months from AF diagnosis resulted in higher freedom from AA recurrence and is associated with fewer safety events in a real-world evaluation. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT02752737


  • Open Access

    Implementing remote monitoring for COVID-19 patients in primary care

    by Svea Holtz, Susanne M. Koehler, Peter Jan Chabiera, Nurlan Dauletbaev, Kim Deutsch, Zoe S. Oftring, Dennis Lawin, Lukas Niekrenz, Teresa Euler, Rainer Gloeckl, et al.

    Background: In Germany, most patients with coronavirus disease 2019 (COVID-19) are treated in an outpatient setting. To improve assessments of the health status of COVID-19 outpatients, various remote monitoring models have been developed. However, little information exists on experiences acquired with remote monitoring in an outpatient setting, particularly from a patient perspective. The aim of our ‘COVID-19@home’ study was therefore to implement and evaluate an app-based remote monitoring concept for acute and post-acute COVID-19-patients in primary care. In this paper, we focus on the patients’ evaluation of our remote monitoring approach. Methods: Patients with acute COVID-19 measured heart rate, blood pressure, oxygen saturation, and body temperature daily for 28 days. Patients with post-acute COVID-19 determined the same parameters for 12 weeks, supplemented by lung parameters and daily step count. The data were documented using the ‘SaniQ’ smartphone app. COVID-19 symptoms were assessed daily using an app-based questionnaire. Patients’ GPs could access the data on the ‘SaniQ Praxis’ telemedicine platform. We used an app-based questionnaire consisting of 11 questions presented with a 4-point Likert scale to evaluate patient satisfaction. Data were analyzed descriptively. Results: Of the 51 patients aged 19-77 years that participated in the study, 42 completed the questionnaire. All patients rated home monitoring as ‘very good’ or ‘rather good’ and were able to integrate the measuring processes into their daily routines. Overall, 93% would recommend the app and the measuring devices to their family and friends. About 60% felt that their COVID-19 treatment had benefited from home monitoring. Only few patients were unsettled by the app and use of the measuring devices. During the course of the study, the implementation process was optimized. Conclusions: The use of remote monitoring in COVID-19 patients is feasible and was evaluated positively by most study patients. However, it is difficult to imagine how general practices could cope with monitoring patients with acute diseases without any further organizational support. Future research should address cost-effectiveness and changes in such clinical outcomes as hospitalization and mortality.


  • Open Access

    Prolonged mHealth-Based Arrhythmia Monitoring in Patients With Hypertrophic Cardiomyopathy (HCM-PATCH): Protocol for a Single-Center Cohort Study

    by Sophia Schulze Lammers, Thorsten Lawrenz, Dennis Lawin, Annika Hoyer, Christoph Stellbrink, Urs-Vito Albrecht

    Background: Patients with hypertrophic cardiomyopathy (HCM) are at increased risk of sudden cardiac death (SCD) due to ventricular arrhythmias and other arrhythmias. Screening for arrhythmias is mandatory to assess the individual SCD risk, but long-term electrocardiography (ECG) is rarely performed in routine clinical practice. Intensified monitoring may increase the detection rate of ventricular arrhythmias and identify more patients with an increased SCD risk who are potential candidates for the primary prophylactic implantation of an implantable cardioverter-defibrillator. To date, reliable data on the clinical benefit of prolonged arrhythmia monitoring in patients with HCM are rare. Objective: This prospective study aims to measure the prevalence of ventricular arrhythmias in patients with HCM observed by mobile health (mHealth)–based continuous rhythm monitoring over 14 days compared to standard practice (a 24- and 48-h long-term ECG). The frequency of ventricular arrhythmias in this 14-day period is compared with the frequency in the first 24 or 48 hours for the same patient (intraindividual comparison). Methods: Following the sample size calculation, 34 patients with a low or intermediate risk for SCD, assessed by the HCM Risk–SCD calculator, will need to be recruited in this single-center cohort study between June 2023 and February 2024. All patients will receive an ECG patch that records their heart activity over 14 days. In addition, cardiac magnetic resonance imaging and genetic testing data will be integrated into risk stratification. All patients will be asked to complete questionnaires about their symptoms; previous therapy; family history; and, at the end of the study, their experience with the ECG patch-based monitoring. Results: The Hypertrophic Cardiomyopathy: Clinical Impact of a Prolonged mHealth-Based Arrhythmia Monitoring by Single-Channel ECG (HCM-PATCH) study investigates the prevalence of nonsustained ventricular tachycardia (ie, ≥3 consecutive ventricular beats at a rate of 120 beats per minute, lasting for <30 seconds) in low- to intermediate-risk patients with HCM (according to the HCM Risk–SCD calculator) with additional mHealth-based prolonged rhythm monitoring. The study was funded by third-party funding from the Department of Cardiology and Intensive Care Medicine, University Hospital Ostwestfalen-Lippe of Bielefeld University in June 2023 and approved by the institutional review board in May 2023. Data collection began in June 2023, and we plan to end the study in February 2024. Of the 34 patients, 26 have been recruited. Data analysis has not yet taken place. Publication of the results is planned for the fall of 2024. Conclusions: Prolonged mHealth-based rhythm monitoring could lead to differences in the prevalence of arrhythmias compared to 24- and 48-hour long-term ECGs. This may lead to improved identification of patients at high risk and trigger therapeutic interventions that may provide better protection from SCD or atrial fibrillation–related complications such as embolic stroke. Trial Registration: Deutsches Register Klinischer Studien DRKS00032144; https://tinyurl.com/498bkrx8


  • Open Access

    Cryoballoon ablation of atrial fibrillation in octogenarians: one year outcomes from the cryo global registry

    by Dennis Lawin, Thorsten Lawrenz, K. R. Julian Chun, Hong-Euy Lim, Valentine Obidigbo, Jada M. Selma, Peter Peytchev, Dinh Quang Nguyen, Csaba Földesi, Christoph Stellbrink, et al.

    Background: Limited information is available on the safety and efficacy of cryoballoon ablation (CBA) in elderly patients with atrial fibrillation (AF). Moreover, global utilization of CBA in this population (≥ 80 years old) has not been reported. This study’s objectives were to determine the use, efficacy, and safety of CBA to treat octogenarians suffering from AF. Methods: In this sub-analysis of the Cryo Global Registry, 12-month outcomes of treating AF via CBA in octogenarians were compared to patients < 80 years old. Efficacy was evaluated as time to a ≥ 30 s atrial arrhythmia (AA) recurrence. Healthcare utilization was determined via repeat ablations and hospitalizations. Improvement upon disease burden was evaluated through patient reporting of symptoms and the EQ-5D-3L quality of life (QoL) survey. Results: The octogenarian cohort (n = 101) had a higher prevalence of females (51.5% vs 35.7%) and CHA2DS2-VASc scores (4.2 ± 1.3 vs 2.0 ± 1.5) compared to the control cohort (n = 1573, both p < 0.01). Even when adjusting for baseline characteristics and antiarrhythmic drug usage, freedom from AA recurrence at 12 months (80.6% vs 78.9%, HRadj:0.97 [95% CI:0.59–1.58], p = 0.90) was comparable between octogenarians and control, respectively. Similar serious adverse event rates were observed between octogenarians (5.0%) and control (3.2%, p = 0.38). The groups did not differ in healthcare utilization nor reduction of AF-related symptoms from baseline to follow-up, but both experienced an improvement in QoL at 12 months. Conclusions: Despite more age-related comorbidities, CBA is a safe and effective treatment for AF in octogenarians, with efficacy and adverse events rates akin to ablations performed in younger patients. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT02752737 Graphical